A platform for brain network sensing and stimulation with quantitative behavioral tracking: Application to limbic...

Area of Science:

• Neurology
• Neuroscience
• Biomedical Engineering

Background:

• Temporal lobe epilepsy (TLE) is a prevalent neurological disorder causing recurrent seizures, often linked to limbic network dysfunction.
• Patients with TLE frequently experience comorbidities affecting memory, mood, and sleep (MMS).
• Anterior nucleus of the thalamus deep brain stimulation (ANT-DBS) is an established therapy, yet optimal stimulation parameters require further investigation.

Purpose of the Study:

• To develop and evaluate a neurotechnology platform for real-time tracking of seizures and MMS in TLE patients undergoing ANT-DBS.
• To optimize ANT-DBS parameters by correlating brain activity with cognitive and behavioral outcomes.
• To compare the efficacy of low-frequency versus high-frequency ANT-DBS in TLE.

Main Methods:

• A neurotechnology platform was created for data streaming from an investigational brain sensing-stimulation implant to mobile devices and a cloud environment.
• Artificial Intelligence (AI) algorithms were employed to accurately identify seizures, interictal epileptiform spikes, and wake-sleep brain states.
• Remote cognitive and behavioral assessments (memory, mood) were administered to densely sample patient responses during ANT-DBS.

Main Results:

• Both low-frequency and high-frequency ANT-DBS demonstrated seizure reduction.
• Low-frequency ANT-DBS exhibited superior seizure reduction compared to high-frequency stimulation.
• Patients receiving low-frequency ANT-DBS showed significant improvements in sleep quality and memory function.

Conclusions:

• Synchronized brain sensing and behavioral tracking offer a promising approach for optimizing neuromodulation therapies like ANT-DBS.
• Low-frequency ANT-DBS emerges as a potentially more effective strategy for managing TLE seizures and associated MMS comorbidities.
• The developed neurotechnology platform facilitates personalized treatment adjustments for improved patient outcomes in TLE.